论文部分内容阅读
Objective: The aim of the study was to observe the cardiac toxicity caused by different doses of epirubicin in the adjuvant treatment of breast cancer and to evaluate the long-term efficacy. Methods: The 180 cases of breast cancer patients received epirubicin based adjuvant chemotherapy. The patients were randomly assigned to high-dosage group(90 mg/m2), medium-dosage group(70 mg/m2) and low-dosage group(50 mg/m2), the primary endpoint was cardiac toxicity. The secondary outcomes were the 5-year overall survival(OS) and 5-year disease-free survival(DFS). Results: During chemotherapy, the clinical symptoms such as palpitation, dyspnea and paroxysmal nocturnal dyspnea occurred in 6 patients with the high-dosage group, 4 patients with the medium-dosage group and 3 patients with the low-dosage group. The number of patients who had changed in electrocardiogram(ECG) was 7, 5 and 4 in three groups, respectively. The echocardiographic showed each group had only one case with LVEF < 50%, there was no significantly difference(P > 0.05). In the three groups, the 5-year DFS rates were 73.3%(44/60) in high-dose group, 53.3%(32/60) in medium-dose group and 41.6%(25/60) in low dose group. The 5-year OS rates were 85.0%(51/60), 68.3%(41/60) and 58.3%(35/60) in three groups, respectively. The differences were statistically significant(P < 0.05). Conclusion: The high-dose epirubicin in adjuvant chemotherapy with CEF(cyclophosphamide, epirubicin and fluorouracil) regimen could improve the 5-year OS rate and 5-year DFS rate on patients of breast cancer. The cardiotoxicity was mild-moderate and well tolerated.
Objective: The aim of the study was to observe the cardiac toxicity caused by different doses of epirubicin in the adjuvant treatment of breast cancer and to evaluate the long-term efficacy. Methods: The 180 cases of breast cancer patients received epirubicin based adjuvant chemotherapy. The patients were randomly assigned to high-dosage groups (90 mg / m2), medium-dosage groups (70 mg / m2) and low-dosage groups the 5-year overall survival (OS) and 5-year disease-free survival (DFS). Results: During chemotherapy, the clinical symptoms such as palpitation, dyspnea and paroxysmal nocturnal dyspnea occurred in 6 patients with the high-dosage group 4 The patients with the medium-dosage group and 3 patients with the low-dosage group. The number of patients who had changed in electrocardiogram (ECG) was 7, 5 and 4 in three groups, respectively. The echocardiographic showed each group had only one case with LVEF <50%, there In the three groups, the 5-year DFS rates were 73.3% (44/60) in high-dose group, 53.3% (32/60) in medium-dose group and 41.6% The 5-year OS rates were 85.0% (51/60), 68.3% (41/60) and 58.3% (35/60) in three groups, respectively. significant (P <0.05). Conclusion: The high-dose epirubicin in adjuvant chemotherapy with CEF (cyclophosphamide, epirubicin and fluorouracil) regimen could improve the 5-year OS rate and 5-year DFS rate on patients of breast cancer. The cardiotoxicity was mild-moderate and well tolerated.